Amazon Pharmacy's low-priced Wegovy rollout raises fresh concerns about pricing power and market share for telehealth players ...

Hims & Hers Health (HIMS) is back in focus as investors reassess its telehealth model, weighing GLP-1 related interest and ...

Fintel reports that on January 12, 2026, Evercore ISI Group initiated coverage of Hims & Hers Health (NYSE:HIMS) with a ...

For investors wondering whether Hims & Hers Health still offers good value after its rise as a telehealth brand, or if the ...

The core challenge for Hims & Hers stems from escalating competition. Amazon Pharmacy has disrupted the market by launching a low-cost offering for weight-loss therapies similar to Wegovy. Market ...

The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

Hims & Hers stock has nosedived in the past few months. It has dived by over 56% from its highest point in July last year ...

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international ...

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space. This is bringing a new class of tech-driven innovators to the forefront.

Based on current trajectories, analysts project that HIMS stock could reach $52 by December 2027, representing a potential 65% return from its current price of $32. The company’s Q3 revenue of $600 ...

Hims & Hers is down 30% but still a Buy: margin expansion, GLP-1 clarity, new hormone care, and global growth. Learn more ...

Hims & Hers (NYSE: HIMS) stock investors desperately need some positive news following the stock price crash in late June. Where to invest $1,000 right now? Our analyst team just revealed what they ...